📣 VC round data is live. Check it out!
- Public Comps
- Azenta
Azenta Valuation Multiples
Discover Azenta's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Clinica Baviera, OPKO Health, Vazyme Biotech, CareDx and more.
Azenta Overview
About Azenta
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Founded
1978
HQ

Employees
3.0K
Website
Financials (LTM)
EV
$755M
Valuation Multiples
Start free trialAzenta Financials
Azenta reported last 12-month revenue of $598M and EBITDA of $62M.
In the same LTM period, Azenta generated $268M in gross profit, $62M in EBITDA, and $19M in net income.
Revenue (LTM)
Azenta P&L
In the most recent fiscal year, Azenta reported revenue of $594M and EBITDA of $66M.
Azenta is profitable as of last fiscal year, with gross margin of 46%, EBITDA margin of 11%, and net margin of 4%.
Financial data powered by Morningstar, Inc.
Azenta Stock Performance
Azenta has current market cap of $1B, and enterprise value of $755M.
Market Cap Evolution
Azenta's stock price is $23.43.
Azenta share price increased by 2.4% in the last 30 days, and decreased by 23.9% in the last year.
Azenta has an EPS (earnings per share) of $0.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $755M | $1B | 1.1% | 2.4% | 10.9% | -23.9% | $0.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAzenta Valuation Multiples
Azenta trades at 1.3x EV/Revenue multiple, and 12.1x EV/EBITDA.
EV / Revenue (LTM)
Azenta Financial Valuation Multiples
As of June 3, 2026, Azenta has market cap of $1B and EV of $755M.
Azenta has a P/E ratio of 56.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Azenta Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Azenta Margins & Growth Rates
Azenta grew revenue by 1% but EBITDA decreased by 9% in the last fiscal year.
In the most recent fiscal year, Azenta reported gross margin of 46%, EBITDA margin of 11%, and net margin of 4%.
Azenta Margins
Azenta Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Azenta Operational KPIs
Azenta's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Azenta's Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Azenta's Rule of X is 16% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Azenta Competitors
Azenta competitors include Clinica Baviera, OPKO Health, Vazyme Biotech, CareDx, Personalis, Eckert & Ziegler, Guangzhou Wondfo Biotech, Novogene, Daan Gene and NeoGenomics.
Most Azenta public comparables operate across Laboratory Services, Diagnostics & Genomics and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.1x | 2.9x | 10.7x | 10.5x | |||
| 1.8x | 1.9x | (26.9x) | (8.6x) | |||
| 4.0x | 3.8x | 38.4x | 24.0x | |||
| 2.6x | 2.4x | 30.9x | 24.4x | |||
| 13.9x | 13.2x | (13.7x) | (10.8x) | |||
| 3.0x | 3.0x | 9.9x | 10.1x | |||
| 3.3x | 3.0x | 37.7x | 16.3x | |||
| 1.9x | 1.9x | 12.5x | 12.6x | |||
This data is available for Pro users. Sign up to see all Azenta competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Azenta
Azenta has acquired 5 companies to date.
Last acquisition by Azenta was on March 3rd 2026. Azenta acquired Biocentre for $28M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Azenta
| Description | Biocentre is a UK biomedical research institute for academic, pharmaceutical, and biotech sectors. | Ziath is a UK-based manufacturer of 2D barcode readers for decoding DataMatrix codes on cryogenic sample tubes. Headquartered near Cambridge, its products like the Mirage and Express models support high-throughput tube picking and rack scanning in biobanking, pharma labs, and research facilities worldwide via https://ziath.com/. | B Medical Systems is a Luxembourg-headquartered manufacturer and distributor of medical refrigeration, blood storage, and vaccine cold chain equipment. Operating for over 35 years, the company supplies ultra-low temperature freezers, blood bank refrigerators, and transport solutions certified under ISO 13485 and WHO prequalification standards. Its products serve hospitals, labs, and governments in more than 100 countries through a network of 150 partners, including deployments for COVID-19 vaccine distribution. | Barkey Holding is a Leopoldshöhe-headquartered manufacturer of specialized medical devices for temperature management in healthcare environments. Its product lineup features the Plasmatherm dry thawing system for plasma bags, blood products, and cell materials including CAR-T cells, alongside fluid warming sets, irrigation fluid warmers, and warming cabinets for sterile goods. These devices serve anesthesia departments, operating theaters, intensive care units, recovery areas, and blood banks across Europe and beyond. | |
| HQ Country | |||||
| HQ City | Stockport | Cambridge | Hosingen | Cologne | |
| Deal Date | 3 Mar 2026 | 3 Feb 2023 | 8 Aug 2022 | 8 Jun 2022 | |
| Valuation | $28M | $16M | $443M | $86M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Azenta acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Azenta
| When was Azenta founded? | Azenta was founded in 1978. |
| Where is Azenta headquartered? | Azenta is headquartered in United States. |
| How many employees does Azenta have? | As of today, Azenta has over 3K employees. |
| Who is the CEO of Azenta? | Azenta's CEO is John P. Marotta. |
| Is Azenta publicly listed? | Yes, Azenta is a public company listed on Nasdaq. |
| What is the stock symbol of Azenta? | Azenta trades under AZTA ticker. |
| When did Azenta go public? | Azenta went public in 1995. |
| Who are competitors of Azenta? | Azenta main competitors include Clinica Baviera, OPKO Health, Vazyme Biotech, CareDx, Personalis, Eckert & Ziegler, Guangzhou Wondfo Biotech, Novogene, Daan Gene, NeoGenomics. |
| What is the current market cap of Azenta? | Azenta's current market cap is $1B. |
| What is the current revenue of Azenta? | Azenta's last 12 months revenue is $598M. |
| What is the current revenue growth of Azenta? | Azenta revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Azenta? | Current revenue multiple of Azenta is 1.3x. |
| What is the current EBITDA of Azenta? | Azenta's last 12 months EBITDA is $62M. |
| What is Azenta's EBITDA margin? | Azenta's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Azenta? | Current EBITDA multiple of Azenta is 12.1x. |
| What is the current FCF of Azenta? | Azenta's last 12 months FCF is $40M. |
| What is Azenta's FCF margin? | Azenta's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Azenta? | Current FCF multiple of Azenta is 19.0x. |
| How many companies Azenta has acquired to date? | As of June 2026, Azenta has acquired 5 companies. |
| What was the largest acquisition by Azenta? | $443M acquisition of B Medical Systems on 8th August 2022 was the largest M&A Azenta has done to date. |
| In how many companies Azenta has invested to date? | Azenta hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Azenta
Lists including Azenta
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


